Attention deficit/hyperactivity disorder: pharmacotherapy.
Year: 2005
Type: article
Abstract: Pharmacotherapy, one of the effective modalities of treatment for attention deficit/hyperactivity disorder (ADHD), was discovered serendipitously and, until recently, consisted primarily of short-acting methylphenidate and dextroamphetamine compounds. The US Food and Drug Administration's (FDA) approval of Concerta in 2000 followed by approval of additional long-acting methylphenidate (Ritalin LA; Metadate CD) and amphetamine formulations (Adderall XR) expanded the repertoire. By providing sustained efficacy for most of the school day, mid-day administration is avoided, privacy is preserved, and adherence to treatment improves. In 2001, an isomer preparation of methylphenidate, Focalin, was approved, and in 2002, Strattera, a selective noradrenergic agent expanded treatment options to non-controlled agents. At this time, stimulant preparations continue to remain the first-line agents due to their unparalleled efficacy and safety record. However, current treatment remains empirical due to lack of scientific data guiding the choice of agent as well as dose.
Source: PubMed Central
Author: Josephine Elia
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1850840401